Abstract:
A method for fabricating a magnetic transducer is described. The magnetic transducer includes a pole having a pole tip and a flared region. The method Includes providing a first mask layer on the pole and providing a second mask layer on the first mask layer. The first mask layer is soluble in a predetermined solution and has a first thickness. The second mask layer has a second thickness greater than the first thickness. The method also includes forming a mask from the first mask layer and the second mask layer. The step of forming the mask layer includes using the predetermined solution. The mask has a pattern that exposes a portion of the pole tip and covers a portion of the flared region. The method also includes providing a wrap-around shield on at least the pole tip.
Abstract:
Methods of patterning a material are disclosed. A first resist pattern is formed on a field. A protective layer is formed over the first resist pattern and at least a portion of the field. A second resist pattern is formed over a portion of the protective layer. A portion of a material to be patterned deposited adjacent to the first and second resist patterns is removed.
Abstract:
An optical mask for providing a pattern for portion of an electronic device, such as a magnetic recording transducer, is disclosed. The optical mask includes a device feature and at least one detached correction feature. The device feature includes a corner corresponding to a device corner of the pattern. The device corner has an angle of greater than zero degrees and less than one hundred eighty degrees. The at least one detached correction feature resides in proximity to but is physically separated from the corner. Each of the at least one detached correction feature is sub-resolution.
Abstract:
A method for fabricating a magnetic recording transducer having a magnetic writer pole with a short effective throat height is provided. In an embodiment, a writer structure comprising a magnetic writer pole having a trailing bevel and a nonmagnetic stack on the top surface of the writer pole is provided. A dielectric write gap layer comprising alumina is deposited over the trailing bevel section and the nonmagnetic stack; and at least one etch stop layer is deposited over the dielectric write gap layer. A layer of nonmagnetic fill material is deposited over the etch stop layer and to form a nonmagnetic bevel by performing a dry etch process. The etch stop layer(s) are removed from the short throat section; and a trailing shield is deposited over the short throat section, nonmagnetic bevel, and nonmagnetic stack top surface.
Abstract:
An approach is provided distributing content to multiple devices. Specifically, a distribution module causes, at least in part, a rendering of at least one user interface for distributing content among at least one device and one or more other devices with connectivity to the at least one device. The distribution module then causes, at least in part, one or more segmentations of the at least one user interface, wherein the one or more segmentations are associated with the at least one device, respective one or more of the one or more other devices, or a combination thereof. Next, the distribution module determines one or more interactions with the at least one user interface, the one or more segmentations, or a combination thereof to cause, at least in part, a distribution of the content.
Abstract:
A filar includes an inner conductive core that is formed of a low-resistivity material such as silver having a resistivity of less than 20 μΩ per centimeter. A conductive coil is provided around the core to form a filar. This coil is formed of a biocompatible alloy or super alloy having an ultimate tensile strength (UTS) of between 150 kilo pounds per square inch (ksi) and 280 ksi at room temperature. Examples of such alloys include CoCrMo, CoFeCrMo, and CoFeNiCrMo. In one specific embodiment, the alloy is MP35N (CoNiCrMo), which may be low-titanium (“low-ti”) MP35N. One or more such filars may be included within a wire. This wire may be carried by an implantable medical apparatus such as a lead, lead extension, or catheter. The wire may electrically couple elements such as connector electrodes to conducting electrodes or sensors.
Abstract:
This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID NO: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
Abstract translation:本申请涉及重组人类干扰素样蛋白。 在一个实施方案中,与天然存在的人干扰素α2b(HuIFN-α2b)相比,描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地,多核苷酸选自各自具有与SEQ ID:No.1至少93%相同的序列的多核苷酸,并且所述蛋白质选自蛋白质组,其各自具有与SEQ ID NO:至少85%相同的氨基酸序列 包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗(例如病毒性疾病和癌症)有反应的病症。
Abstract:
In certain embodiments of the invention, a serializer has (a) an initial, transfer stage that transfers incoming parallel data from a relatively slow timing domain to a relatively fast timing domain and (b) a final, serializing stage that converts the parallel data into serialized data. Between the transfer stage and the serializing stage is an update stage that (i) buffers data between the initial and final stages and (ii) can be used to toggle the serializer between an N−1 operating mode (that serializes (N−1) bits of parallel data) and an N+1 operating mode (that serializes (N+1) bits of parallel data) to achieve a net N:1 gearing ratio where N is an odd integer. The serializer can be configurable to support other gearing ratios as well.
Abstract:
A method is disclosed for conducting a query to transform data in a pre-existing database, the method comprising: collecting database information from the pre-existing database, the database information including inconsistent dimensional tables and fact tables; running an entity discovery process on the inconsistent dimensional tables and the fact tables to produce entity mapping tables; using the entity mapping tables to resolve the inconsistent dimensional tables into resolved dimensional tables; and running the query on a resolved database to obtain a query result, the resolved database including the resolved dimensional table.
Abstract:
This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
Abstract translation:本申请涉及重组人类干扰素样蛋白。 在一个实施方案中,与天然存在的人干扰素α2b(HuIFN-α2b)相比,描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地,多核苷酸选自各自具有与SEQ ID:No.1至少93%相同的序列的多核苷酸,并且所述蛋白质选自蛋白质组,其各自具有与SEQ ID NO:至少85%相同的氨基酸序列 否:2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗(例如病毒性疾病和癌症)有反应的病症。